Dr. Christopher Flowers showcases a comprehensive and updated analysis of the ROSEWOOD study, evaluating the efficacy and safety of combining zanubrutinib with obinutuzumab versus obinutuzumab monotherapy.
Revisit Every OncLive On Air Episode From April 2024
Revisit the OncLive On Air Episodes From February 2024
Uproleselan Plus Chemotherapy Misses OS End Point in R/R AML
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
Which JAK Inhibitor in Myelofibrosis: Deciding Factors in Treatment Selection
Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma
Dr Liu Previews ASCO 2024 Lung Cancer Data
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer